RGDXQ (Response Genetics) LT-Debt-to-Total-Asset: 0.10 (As of Dec. 2015)


What is Response Genetics LT-Debt-to-Total-Asset?

Response Genetics RGDXQ -98.00% LT-Debt-to-Total-Asset is 0.10 as of Dec. 2015.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Response Genetics's long-term debt to total assests ratio for the quarter that ended in Dec. 2015 was 0.10.

Response Genetics's long-term debt to total assets ratio declined from Jun. 2014 (0.13) to Dec. 2015 (0.10). It may suggest that Response Genetics is progressively becoming less dependent on debt to grow their business.

Response Genetics  (OTCPK:RGDXQ) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Response Genetics LT-Debt-to-Total-Asset Related Terms

Response Genetics LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Response Genetics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Response Genetics LT-Debt-to-Total-Asset Chart

Response Genetics Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 0.01 0.06 0.15 0.10

Response Genetics Quarterly Data
Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Dec15
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.13 0.59 0.15 1.01 0.10

Response Genetics LT-Debt-to-Total-Asset Calculation

Response Genetics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2015 is calculated as

LT Debt to Total Assets (A: Dec. 2015 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2015 )/Total Assets (A: Dec. 2015 )
=4.918/48.884
=0.10

Response Genetics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2015 is calculated as

LT Debt to Total Assets (Q: Dec. 2015 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2015 )/Total Assets (Q: Dec. 2015 )
=4.918/48.884
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.10 mean?
Response Genetics (RGDXQ) has a LT-Debt-to-Total-Asset of 0.10 as of Dec. 2015. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Response Genetics and its competitors.
Is Response Genetics' LT-Debt-to-Total-Asset too high?
Response Genetics' current LT-Debt-to-Total-Asset is 0.10.
How does Response Genetics' LT-Debt-to-Total-Asset compare to PSID and GBSN?
Response Genetics' LT-Debt-to-Total-Asset of 0.10 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Medical Diagnostics & Research company?
A good LT-Debt-to-Total-Asset depends on the Medical Diagnostics & Research industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Response Genetics and its competitors. Response Genetics's current LT-Debt-to-Total-Asset is 0.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Response Genetics stock overvalued right now?
Response Genetics (RGDXQ) has a current LT-Debt-to-Total-Asset of 0.10. The current LT-Debt-to-Total-Asset is 0.10. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Response Genetics (RGDXQ), the current LT-Debt-to-Total-Asset is 0.10 as of Dec. 2015. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Response Genetics Business Description

Address 201 Route 17 North, 2nd Floor, Rutherford, NJ, USA, 07070
Response Genetics Inc develops and sells diagnostic tests. It provides molecular- and biomarker-based tests and services which enables physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment. The group generates revenue from providing Biopharma Services, Clinical Services, and Discovery Services, of which majority of the revenue is derived from providing Biopharma Services. Biopharma services provide companies with customized solutions for patient stratification and treatment selection through molecular- and biomarker-based testing services, customized assay development and trial design consultation. The firm operates in the US and internationally and generates prime revenue from the US.